TraumaConnect®: A New Digital Lifeline for Australians Living with Trauma--and the Professionals Who Support Them
MELBOURNE, Australia, May 29, 2025 /PRNewswire/ -- The Cairnmillar Institute is proud to announce the launch of TraumaConnect®, a groundbreaking digital mental health platform designed to support Australians affected by trauma—while also empowering the clinicians, carers, and support workers who walk alongside them.
Developed by a team of psychologists, researchers, and people with lived experience, TraumaConnect® is the first trauma-informed digital platform of its kind in Australia. It offers 24/7 access to evidence-based tools, resources, and real-time messaging support, helping to bridge the critical gaps in care—between appointments, during long waitlists, or when traditional services are out of reach.
"Too many people are being told to wait—for services, for answers, for recovery," said Dr Kathryn von Treuer, CEO and Provost at the Cairnmillar Institute. "TraumaConnect® ensures that no one is left without support. It meets people where they are, with tools they can use immediately to feel seen, heard, and supported."
The platform is designed not only for individuals navigating trauma, but also for the healthcare professionals who support them. Clinicians can use TraumaConnect® to extend care beyond the therapy room, reduce burnout, and access a growing library of trauma-informed resources that align with best practice. Dedicated tools, forums, articles and practice guides for health professionals implementing trauma-informed care in clinical settings will also be launching on the platform soon.
"Clinicians see this gap every day—the time between appointments, the long waitlists, the moments when people need something right now," said Vicki Smith, Clinical Psychologist and Director of Digital Services at Cairnmillar. "TraumaConnect® bridges that gap with evidence-based tools and real-world compassion."
The platform includes a rich library of articles, videos, podcasts, and lived-experience stories, as well as practical workbooks and tip sheets for emotional wellbeing. A confidential messaging service connects users with trained Australian health professionals and peer workers from 8am–8pm AEST, Monday to Friday. Live webinars and community events led by trauma specialists offer ongoing education and connection.
The human voice is central to TraumaConnect®. Every element has been co-designed and reviewed by people with lived experience, ensuring the platform is not only clinically sound, but also deeply compassionate and relevant.
"As someone with lived experience of trauma, I know how hard it is to find reliable, safe, and gentle support when you're in the thick of it," said Alexandra Paton, a lived experience contributor. "This platform offers something steady and meaningful when life feels uncertain. It's about walking alongside people with information and support they can truly hold onto."
TraumaConnect® is now live and available to individuals, carers, support workers, and organisations. Group memberships are available for teams and communities, with flexible onboarding and support.
Explore the platform at www.traumaconnect.org.au or download the app via the App Store or Google Play.
Media Contact:Vicki SmithDirector of Digital Services and Short CoursesCairnmillar Institutevicki.smith@cairnmillar.org.au
View original content:https://www.prnewswire.com/apac/news-releases/traumaconnect-a-new-digital-lifeline-for-australians-living-with-traumaand-the-professionals-who-support-them-302467806.html
SOURCE Cairnmillar Institute
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma 1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median overall survival of 19.5 months amongst long-term survivors receiving Onivyde ® plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line therapy 2 Dose reductions and/or treatment delays for the management of adverse events enabled patients to stay on treatment longer and achieve high cumulative doses of liposomal irinotecan and oxaliplatin 2 PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS) of 19.5 months among long-term survivors (n=15) with metastatic pancreatic adenocarcinoma (mPDAC) treated with the Onivyde ® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line treatment (n=120), with younger age at diagnosis, and certain tumor and metastasis locations associated with long-term survivorship. 2 Pancreatic adenocarcinoma (PDAC) is the most common type of cancer that forms in the pancreas, with more than 60,000 people diagnosed annually in the U.S. and nearly 500,000 people globally.3 , 4 It is often detected after the disease has spread to other parts of the body (metastatic or stage IV)5 and fewer than 20% of people diagnosed with metastatic pancreatic adenocarcinoma (mPDAC) survive longer than one year. 5 , 6 Overall, pancreatic cancer has the lowest five-year survival rate of all cancer types globally and in the U.S. 5 , 6 'When people are diagnosed with metastatic pancreatic adenocarcinoma, the most important question remains: how long will they have with their loved ones,' said Dr. Vincent Chung, Medical Oncologist, City of Hope. 'Findings from the NAPOLI 3 post-hoc analysis provide important context on long-term overall survival with the Onivyde (NALIRIFOX) treatment regimen.' The analysis included patients who survived for 18 months or longer (N=15), with findings showing long-term survivors living with mPDAC had a mOS of 19.5 months (interquartile range [IQR]: 18.8–22.6). 2 Clinical and pathological factors of long-term survivors included younger than average age at time of diagnosis (median age 61.0 (IQR: 49.0–70.5) as well as tumor location. 2 Fewer patients had tumors in the head or tail of the pancreas (53.3% had the main pancreatic tumor located in the body of the pancreas), a substantial proportion had liver metastasis (66.7%) and ≥3 metastatic sites (53.3%). 2 Additionally, findings indicate dose reduction and treatment delays resulted in prolonged exposure and higher cumulative doses of the Onivyde (NALIRIFOX) regimen. 1 Liver metastasis and ≥3 metastatic sites, dose modifications and an otherwise good clinical profile enabled people to achieve a long mOS. 2 Consideration should be taken when interpreting these results as a post-hoc analysis with a small sample size. 'Data from the Phase III NAPOLI 3 trial were the first positive data of its kind in a decade and continue to reinforce the potential for long-term outcomes with the Onviyde (NALIRIFOX) regimen,' said Sandra Silvestri, MD, PhD, Executive Vice President, Chief Medical Officer, Ipsen. 'With people on average living just 4-6 months following diagnosis with pancreatic adenocarcinoma, these data help us to understand the characteristics associated with long-term survival seen in the NAPOLI trial, an important advancement for this difficult-to-treat cancer where data of this kind are scarce.' ENDS About Onivyde (irinotecan liposome injection) Onivyde is a long-circulating liposomal topoisomerase inhibitor. In Onivyde, irinotecan is enclosed in tiny fat particles called liposomes which accumulate in the tumor and release slowly over time. Onivyde is administered via intravenous infusion over 90 minutes every two weeks with recommendations on dosing modifications. Onivyde, as part of the NALIRIFOX regimen (combined with oxaliplatin, fluorouracil (FU) and leucovorin (LV)), is for people living with mPDAC who are treatment naïve or used in combination with FU and LV following gemcitabine-based therapy. Onivyde is not indicated as a single agent for the treatment of adult patients with metastatic pancreatic adenocarcinoma. Ipsen has exclusive commercialization rights for the current and potential future indications for Onivyde in the U.S. Servier, an independent international pharmaceutical company governed by a foundation and with an international presence in 140 countries, is responsible for the commercialization of Onivyde outside of the U.S., Taiwan and Canada. PharmaEngine is a commercial stage oncology company headquartered in Taipei and is responsible for the commercialization of Onivyde in Taiwan. About NAPOLI 3 Study NAPOLI 3 is a randomized, open-label Phase III trial of an Onivyde treatment regimen (NALIRIFOX) in treatment-naïve mPDAC. NAPOLI 3 enrolled 770 patients across 187 trial site locations in 18 countries across Europe, North America, South America, Asia, and Australia. Patients were randomized to receive Onivyde plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX regimen; n=383) twice in a month (days 1 and 15 of 28-day cycle) compared to an injection of nab-paclitaxel and gemcitabine (n=387) administered three times a month (days 1, 8, 15 of a 28-day cycle) . About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen Media contacts Investors Khalid Deojee | +33 666019526 | [email protected] Media Disclaimers and/or Forward-Looking Statements The forward-looking statements, objectives and targets contained herein are based on Ipsen's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words 'believes', 'anticipates' and 'expects' and similar expressions are intended to identify forward-looking statements, including Ipsen's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen's patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen's activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen's partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen's business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen's latest Universal Registration Document, available on References 1 Wainberg et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 Oct 7;402(10409):1272-1281. 2 Chung et al. NAPOLI 3 phase 3 study of NALIRIFOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): final overall survival (OS) analysis and characteristics of the long-term survivors. As presented at ASCO Congress 2025 Chicago, USA 3 American Cancer Society – Cancer Facts and Figures 2024. Available : 4 5 Orth, M., Metzger, P., Gerum, S. et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 14, 141 (2019). Attachment Ipsen PR_ASCO NAPOLI_31052025 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
New York Post
2 hours ago
- New York Post
What is ‘sleep divorce' — and why is this concerning trend becoming more popular?
There's been a dramatic spike in the number of couples agreeing to part ways in the bedroom as Australia's growing sleep crisis worsens. New data shows that nearly one in three Australians are struggling to fall or stay asleep three or more times a week, sparking a rise in the number of couples who have embarked on a 'sleep divorce', opting to get their nightly rest in separate beds or rooms – despite ongoing stigma surrounding the decision. Advertisement The research, conducted by leading sleep device manufacturer ResMed for its 2025 Global Sleep Survey, has revealed sleep deprivation is so bad that almost 1 in 5 (18 per cent) of Australians have called in sick. 6 Nearly one in three Australians are struggling to fall or stay asleep three or more times a week, leading to couples getting their nightly rest in separate beds or rooms. Pixel-Shot – But shockingly, 41 percent of Aussies are choosing to 'just live with' the consequences of a bad night's kip, almost double the global average. 'This year's Resmed Global Sleep Survey found that the top factors causing Australians to have a poor night's sleep are stress (47 percent), followed by anxiety (42 percent) and financial pressures (26 percent),' Dr. Alison Wimms, Director of Medical Affairs for the company, told Advertisement 'Screen time, and inconsistent routines also widely affect sleep in Australia.' 6 41 percent of Aussies are choosing to 'just live with' the consequences of a bad night's kip, almost double the global average. terovesalainen – Some of those not willing to put up with a poor night's sleep have decided to embark on a 'sleep divorce', with 61 percent of Aussies who have ditched their partner at bedtime reporting a better sleep quality. '26 per cent said it improved their relationship, and almost 16 per cent noted a positive impact on their sex life,' Dr. Wimms added. Advertisement 'Sleeping separately can also improve sleep quality by reducing disturbances from different schedules, snoring, or movement during sleep.' However sleeping separately does not work for everybody, with 38 percent of the 1 in 5 Australians who opted for a sleep separation – often due to snoring and restlessness – stating they felt their quality of sleep got worse or remained the same. Alarmingly, almost 1 in 5 of those who have split up at night said they felt their relationship and sex life took a turn for the worse after sleeping apart. Advertisement Sydney couple's therapist Shahn Baker Sorekli however warns that while a sleep separation 'can be helpful in some circumstances', he doesn't always recommend it. 6 According to a survey, 38 percent of the 1 in 5 Australians who opted for a sleep separation – often due to snoring and restlessness – said they felt their quality of sleep worsen or remained the same. motortion – 'The main reason is coming together at the end of the night allows for a bit of a nice routine for the relationship where you can have a moment of connection and intimacy,' podcast, From the Newsroom. 'I'm not talking about, you know, long deepened meaningfuls in bed. It might just be a little snuggle, might just be reading next to each other, but kind of coming together at the end of the night. 'Being a couple, just unwinding is just a nice point of connection. And if you can maintain a good sleep routine together, it can just be really healthy for the relationship. So you close off the world, you in your room together, snuggling away.' 6 'If you can maintain a good sleep routine together, it can just be really healthy for the relationship,' couple's therapist Shahn Baker Sorekli says. Allistair F/ – The clinical psychologist, who authored relationship book The 8 Love Links, said that for those who find sleeping apart 'improves sleep quality it's absolutely a good idea'. 'For example, if one person is a really restless sleeper or somebody has a problem with snoring or perhaps somebody does shift work… and it going to add to the relationship tension, that's when it's a good idea,' he shared. Advertisement 'You've just got to be careful not to get into any kind of the pitfalls around it. 6 If sleeping together is 'going to add to the relationship tension, that's when it's a good idea,' Sorekli said about when it is appropriate for separate sleeping arrangements. WavebreakMediaMicro – Dr. Wimms noted that it is often women who report poorer sleep quality and higher rates of mood disruptions than men, explaining the gap was noticeable. '38 per cent of Australian women struggle to fall asleep at least 3 nights a week, compared to 26 per cent of men,' she explained. Advertisement 'This is consistent with global numbers where we see women consistently report more sleep challenges. This may be due to hormonal changes through the month, caregiving responsibilities, or higher stress loads. 6 'We see women consistently report more sleep challenges. This may be due to hormonal changes through the month, caregiving responsibilities, or higher stress loads,' Dr. Wimms said. Nattakorn – 'While 4 in 10 Australian women say that their sleep is disrupted by their partner at least a few times a week, most often because of snoring or loud breathing, compared to 28 per cent of men.' The report concluded that sleep has become the 'silent casualty of our busy modern lifestyles', noting the 'lines between work and home more blurred than ever'. Advertisement Pressures such as the rising cost of living in Australia are also building, resulting in poor sleep across the nation. But it's not all bad news, with ResMed stating that Australians have become more curious about how they sleep, with 33 percent monitoring their sleep, up from 18 percent last year. 'This increased curiosity, however, has revealed a gap in action with a staggering 41 per cent of Aussies saying they would just live with poor sleep,' Dr. Wimms said. Advertisement 'This is higher than the 22 per cent globally who indicated that they would do the same. This gap makes it vital for us to drive awareness of the importance of not just knowing, but taking action to improve your sleep health. 'This could be as simple as raising your sleep in a conversation with your healthcare provider or taking an online sleep assessment to learn more about what may be causing your poor sleep.' Those who have spoken out in the past about the benefits of sleeping separately to their partner include Michael and Lisa Wipfli, Sunrise host Edwina Bartholomew and her husband Neil Varcoe as well as popular porn star Annie Knight who recently announced she sleeps in a separate bed to her new fiance Henry Brayshaw.
Yahoo
2 hours ago
- Yahoo
Williamson County veterinary clinic warns cat owners of deadly Bobcat Fever
FAIRVIEW, Tenn. (WKRN) — A Williamson County veterinary clinic is warning cat owners about the dangers of a deadly, tick-borne disease after seeing a surge in cases over the last two weeks. Bobcat Fever, also known as Cytauxzoonosis, is a deadly parasite transmitted to cats by the Lone Star tick, which is known to have one white dot on it. The parasite normally lives in bobcats without causing illness, however, when domestic cats are infected, they often die within 72 hours of first symptoms, which may include fever, lack of energy, decreased appetite, and yellow skin or eyes, deadly, according to Fairview Animal Clinic. Over the last few weeks, Fairview Animal Clinic has seen nine cases of Bobcat Fever. 'We haven't had this many cases in such a short two-week period, so I'm kind of nervous about what's going to happen over this the rest of the summer since it's a long tick season, and it goes all the way to the fall,' said Dr. Eric Fold, associate veterinarian at Fairview Animal Clinic. More than a dozen arrested by Lebanon police in 'targeted operation' Dr. Simone Godwin, a relief veterinarian at Fairview Animal Clinic, said even with aggressive treatment including hospitalization, antimicrobials, and supportive care, the disease is often fatal. In this recent cluster of cases at Fairview Animal Clinic, 78% of cats died or were euthanized. Of the five that were treated, only one survived. Additionally, one cat who did not receive treatment survived. 'So far, we've only had a 20% success rate, and it's really hard on the cats,' Fold said. 'They're very, very sick, and a lot of owners actually elect to euthanize because of the poor prognosis, the just the state of their cat when they bring it in, and it's pretty expensive. The medications are very, very pricey to obtain.' Fold said early detection is crucial as survival rates drop drastically without treatment. 📧 Have breaking news come to you: → 'We've got to get our cats on the prevention, and if you do notice any signs of illness in your cat, bring it in as fast as you can that way we can get them started,' Fold said. 'We've seen some success with it, but it's still a very difficult disease to try to manage.' Dr. Danielle Grigsby, owner of Fairview Animal Clinic, said keeping cats indoors and on year-round flea and tick prevention is the best way to prevent Bobcat Fever and a host of other issues that outdoor cats are at risk for, like trauma, eating something toxic, and other infections. Since some of the fipronil products can take up to 48 hours to actually kill the tick, Fold said the clinic is recommending some of the prescription-based prevention products, such as the Seresto® Flea and Tick Collar for Cats. 'The problem that we're seeing with the Seresto® collar is that the owners actually aren't keeping them tight enough on the cats so they don't actually have contact with the skin, so it has to be tight enough to actually transmit the medication to the cat,' Fold said. 'Just make sure that you go by the label instructions, but it's usually going to be one to two fingers tight, where you can only slip one or two fingers between the cat and the collar. ⏩ Even though the disease does not affect dogs or humans, veterinary experts said both can carry ticks indoors which could ultimately infect a cat. 'The life expectancy of outdoor cats is only 2-5 years, versus up to 15 for indoor cats, Godwin said. 'Your veterinarian can help you make the best decision on prevention products and lifestyle changes to make sure your cat lives a long and healthy life.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
